Anti-inflammatory antibody shows safety in Alzheimer's but lacks clear efficacy

A randomized phase 1b trial in 40 participants has tested for the first time in humans a PD-L1 antibody designed to reduce neuroinflammation in early Alzheimer's disease, administered in four doses every three months across escalating scales from 1 to 30 mg/kg. Results confirm an impeccable safety profile—no serious adverse events or amyloid-related imaging abnormalities detected—but reveal an uncomfortable finding: directional improvements in cerebrospinal fluid biomarkers of neuronal and synaptic damage favored the highest dose (30 mg/kg) at 48 weeks, yet none reached statistical significance given the limited sample size. The approach exemplifies the dominant strategy in chronic inflammation research: sabotage a central mechanism of the immune response rather than address root causes—mitochondrial dysfunction, senescent cell burden, intestinal barrier permeability, brain metabolic waste accumulation—which explains why it works in mice but not necessarily in aging human tissue. For longevity-curious readers, the lesson is instructive: promising laboratory biomarkers may not translate to clinical efficacy, and the next phase requires larger cohorts and longer follow-up to determine whether this therapy merits a place in the future anti-inflammatory arsenal.